Williams & Connolly LLP is highly regarded for its expertise in healthcare litigation and investigations, with the firm’s recent workload highlighting its experience in drug pricing trials and other high-profile disputes. The practice is a go-to name for pharmaceutical companies and also counts medical device corporates, product distributors, pharmacy benefit managers, insurance companies and hospitals on its client roster. Enu Mainigi, who is described by clients as ‘ an excellent advocate’, who is ’brilliant, pragmatic, and doesn’t fold under pressure’, and Jennifer Wicht, who leads the firm’s work in government investigations and FCA litigation, jointly lead the Washington DC-based department. Holly Conley and Grant Geyerman are both recommended for civil matters, with Geyerman adding further expertise in criminal cases.
Legal 500 redaktioneller Kommentar
- Profil
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘Williams & Connolly is just the best at what they do. They’re smart, intentional and masters of the art and warfare of litigation. They are incredibly strategic and several steps ahead of their closest competitor.’
‘Enu Mainigi is the best trial attorney I’ve ever worked with and I would not turn to anyone else for a bet-the-company case. She is brilliant, pragmatic, and doesn’t fold under pressure. Enu presents the risks but doesn’t jump to conclusions or use scare tactics. She is an excellent advocate and you definitely want her on your side. Her track record speaks for itself.’
Kernmandanten
- Albertsons Companies
- CVS Health
- Cardinal Health
- Epic Systems
- Medtronic plc
- Celgene and Bristol-Myers Squibb
- United Therapeutics Corp.
- Doctors Hospital
Highlight-Mandate
- Representing CVS Health in a civil antitrust action filed by the New York Attorney General related to the company’s offerings in connection with the 340B Drug Pricing Program.
- Achieved a significant victory on behalf of CVS Health and its subsidiary Caremark in long-running litigation where two drug wholesalers argue that by administering formularies and obtaining drug rebates, PBMs create incentives for manufacturers to drive up prices of certain drugs, including EpiPen.
Anwält*innen
Praxisleitung
Enu Mainigi; Jennifer Wicht
Weitere Kernanwält*innen
Holly Conley; Grant Geyerman